Masami Arai, Etsuko Suzuki, Satoshi Kitamura, Momoyo Otaki, Kaori Kanai, Miwako Yamasaki, Masahiko Watanabe, Yuki Kambe, Koshi Murata, Yuuki Takada, Tetsu Arisawa, Kenta Kobayashi, Rei Tajika, Tomoyuki Miyazaki, Masahiro Yamaguchi, Michael Lazarus, Yu Hayashi, Shigeyoshi Itohara, Alban de Kerchove d'Exaerde, Hiroyuki Nawa, Ryang Kim, Haruhiko Bito, Toshihiko Momiyama, Daiki Masukawa, Yoshio Goshima
Dopamine neurons play crucial roles in pleasure, reward, memory, learning, and fine motor skills and their dysfunction is associated with various neuropsychiatric diseases. Dopamine receptors are the main target of treatment for neurologic and psychiatric disorders. Antipsychotics that antagonize the dopamine D2 receptor (DRD2) are used to alleviate the symptoms of these disorders, but may also sometimes cause disabling side effects such as parkinsonism (catalepsy in rodents). Here we show that GPR143, a G-protein-coupled receptor for L-3,4-dihydroxyphenylalanine (L-DOPA), expressed in striatal cholinergic interneurons enhances the DRD2-mediated side effects of haloperidol, an antipsychotic agent...
January 29, 2024: Journal of Neuroscience